Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1547218 | 1.00 | ACACB (1.00) | ACACBACACA | |
| SCHEMBL2167784 | 1.00 | ACACB (1.00) | ACACBACACA | |
| SCHEMBL1547398 | 1.00 | ACACB (1.00) | ACACBACACA | |
| SCHEMBL1547147 | 0.95 | ACACB (0.90) | ACACBACACA | |
| SCHEMBL15048460 | 0.91 | ACACB (0.83) | ACACBACACA | |
| SCHEMBL1547553 | 0.91 | ACACB (1.00) | ACACBACACA | |
| SCHEMBL1547562 | 0.91 | ACACB (1.00) | ACACBACACA | |
| SCHEMBL1547144 | 0.91 | ACACB (1.00) | ACACBACACA | |
| SCHEMBL2166330 | 0.91 | ACACB (1.00) | ACACBACACA | |
| SCHEMBL1547220 | 0.90 | ACACB (0.82) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470841-B2 | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof | SANOFI (FR) | 2013-06-25 | — | — | US | disclosed |
| US-8470841-B2 | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof | SANOFI (FR) | 2013-06-25 | — | — | US | disclosed |
| US-8470841-B2 | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof | SANOFI (FR) | 2013-06-25 | — | — | US | disclosed |
| US-20110183998-A1 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
| US-20110183998-A1 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
| US-20110183998-A1 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
| EP-2310372-A2 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | Sanofi-Aventis (FR) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010003624-A2 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010003624-A2 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183998-A1 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | CS, CYP11B1, GPR119 | ACACB 1290/4885ACACA 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.